Tango Therapeutics Income Statement (2020-2026) | TNGX

Income Statement Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Revenue & cost
Revenue (Quarter)
18.15M6.79M5.72M5.76M5.77M6.92M6.41M5.77M14.60M10.73M5.43M6.47M19.88M11.61M4.12M5.39M3.18M53.81M
Operating items
Research & Development (Quarter)
19.08M21.92M21.63M24.33M23.74M28.74M29.09M28.04M28.67M27.15M31.34M38.06M38.65M33.26M33.94M36.44M32.81M30.82M32.10M33.53M
Selling, General & Administrative (Quarter)
3.63M4.43M6.07M6.81M7.23M8.10M7.89M8.01M9.17M9.21M9.11M10.66M10.77M11.22M11.09M11.48M11.34M8.92M9.76M15.23M
Other Operating Expenses (Quarter)
-36.97M122.03M-39.10M-32.63M106.64M
Operating Expenses (Quarter)
22.71M26.36M27.70M31.14M30.97M36.84M36.98M36.05M37.84M36.36M40.44M48.73M49.43M7.51M167.06M8.83M44.15M7.11M148.51M48.77M
Operating Income (Quarter)
-4.56M-19.57M-21.98M-25.38M-25.20M-29.92M-30.57M-30.29M-23.25M-25.63M-35.01M-42.26M-29.55M-32.88M-40.91M-42.53M-40.97M14.07M48.09M-48.77M
EBIT (Quarter)
-4.56M-19.57M-21.98M-25.38M-25.20M-29.92M-30.57M-30.29M-23.25M-25.63M-35.01M-42.26M-29.55M-32.88M-40.91M-42.53M-40.97M14.07M48.09M-48.77M
Non-operating items
Non Operating Investment Income (Quarter)
-0.03M-0.01M-0.76M-2.65M-0.94M-0.51M1.15M1.50M0.68M0.84M0.87M-0.44M
Interest & Investment Income (Quarter)
0.01M
Other Non Operating Income (Quarter)
-0.06M-0.05M-0.08M-0.05M0.05M0.52M0.97M1.22M1.15M1.51M2.06M2.18M2.00M1.96M1.48M1.07M0.91M0.70M1.38M1.08M
Non Operating Income (Quarter)
-0.06M0.04M0.12M0.17M0.35M0.87M0.10M2.28M2.60M1.51M-2.32M2.18M2.00M3.77M-4.60M2.69M0.91M0.70M3.06M1.08M
Net income details
EBT (Quarter)
-4.51M-19.53M-21.87M-25.21M-24.86M-29.05M-29.01M-28.01M-20.65M-22.24M-30.72M-37.87M-25.49M-29.11M-37.62M-39.84M-38.82M15.87M-38.80M-45.51M
Tax Provisions (Quarter)
-0.02M0.06M0.18M0.00M0.05M0.06M0.02M0.05M0.04M0.07M0.05M0.03M0.04M-0.01M-0.10M0.00M
Profit After Tax (Quarter)
-4.49M-19.59M-22.05M-25.21M-24.86M-29.05M-29.06M-28.01M-20.71M-22.26M-30.76M-37.91M-25.55M-29.17M-37.67M-39.88M-38.85M15.88M-38.75M-45.51M
Income from Continuing Operations (Quarter)
-4.49M-19.59M-22.05M-25.21M-24.86M-29.05M-29.06M-28.01M-20.71M-22.26M-30.76M-37.91M-25.55M-29.17M-37.62M-39.88M-38.85M15.88M-38.71M-45.51M
Consolidated Net Income (Quarter)
-4.49M-19.59M-22.05M-25.21M-24.86M-29.05M-29.06M-28.01M-20.71M-22.26M-30.76M-37.91M-25.55M-29.17M-37.62M-39.88M-38.85M15.88M-38.71M-45.51M
Income towards Parent Company (Quarter)
-4.49M-19.59M-22.05M-25.21M-24.86M-29.05M-29.06M-28.01M-20.71M-22.26M-30.76M-37.91M-25.55M-29.17M-37.62M-39.88M-38.85M15.88M-38.71M-45.51M
Net Income towards Common Stockholders (Quarter)
-0.76M-19.59M-22.05M-25.21M-24.86M-29.05M-29.06M-28.01M-20.71M-22.26M-30.76M-37.91M-25.55M-29.17M-37.62M-39.88M-38.85M15.88M-38.71M-45.51M
Additional items
EPS (Basic) (Quarter)
-0.09-0.28-0.26-0.29-0.28-0.33-0.33-0.32-0.23-0.23-0.30-0.35-0.24-0.27-0.34-0.36-0.350.14-0.30-0.32
EPS (Weighted Average and Diluted) (Quarter)
-0.09-0.28-0.26-0.29-0.28-0.33-0.33-0.32-0.23-0.23-0.30-0.35-0.24-0.27-0.34-0.36-0.350.13-0.30-0.32
Shares Outstanding (Weighted Average) (Quarter)
48.52M53.40M62.11M87.67M87.84M87.87M87.82M88.19M88.28M97.03M94.57M108.17M108.31M108.51M109.23M110.30M110.54M110.76M116.17M143.58M
Shares Outstanding (Diluted Average) (Quarter)
45.09M53.40M62.11M87.67M87.84M87.87M87.82M88.19M88.28M97.03M94.57M108.17M108.69M108.51M109.23M110.30M110.49M116.17M143.58M
EBITDA (Quarter)
-4.52M-19.60M-22.80M-27.85M-25.80M-29.56M-27.91M-26.50M-20.03M-21.43M-29.90M-38.36M-29.55M-32.88M-40.91M-42.53M-40.97M14.07M48.09M-48.77M
Tax Rate (Quarter)
0.47%-0.32%-0.81%-0.01%-0.18%-0.31%-0.10%-0.15%-0.11%-0.26%-0.19%-0.09%-0.09%-0.06%0.25%0.00%